- 12 oral surgery updates in 2026
- 5 ASC, MOB deals in California
- Hidden OR capacity challenges: 8 perioperative leaders on what’s draining surgical time
- The Aspen Group’s 3-year growth recap: 40 moves
- Florida State University set to acquire Tallahassee hospital
- How Confusing Financial Journeys Undermine Revenue and Trust
- How Confusing Financial Journeys Undermine Revenue and Trust
- Misalignment, Not Malice: Rethinking Generational Conflict in Healthcare
- If AI ‘adds friction, it fails’: How Mayo Clinic scales technology
- As maternity units close, AdventHealth restores OB care in rural Kansas
- Oklahoma officials warn of new opioid
- The new metrics of healthcare technology ROI: What matters to healthcare leaders
- Hoag to launch transplant center in 2027
- MercyOne hospital to transition labor and delivery services
- MercyOne hospital to transition labor and delivery services
- Southeast metros lead US population growth as national gains slow
- 8 Medicare Advantage numbers to know in 2026
- 17 Senate Dems push back on 2027 ACA proposal
- Providence hospital closes inpatient pediatric unit
- Michigan finalizes Medicaid mental health assessment policy changes
- 10 financial notes on USPI’s growth over the past 3 years
- 15 new orthopedic practice, center openings in Q1
- The oral surgery technological revolution
- From Anxiety to Action: How Ambulatory Leaders Are Rebuilding Margins in 2026
- Where GI training may fall short
- What it took to become the world’s first ASC to offer Stryker’s robotic knee tech
- Medtronic’s win in spinal cord stimulator lawsuit upheld
- How the Trump Administration Uses Migrant Kids To Find and Detain Family Members
- Heartland Dental’s 3-year growth recap: 30+ moves
- Cencora’s $10B+ physician acquisition spree: A breakdown
- Tennessee physician practice acquired
- The FTC is coming for healthcare consolidation: 10 things physicians need to know
- Adventist Health sees momentum from insourcing revenue cycle operations
- Oral GLP-1s, COVID preventatives: 3 more drugs in the pipeline, Optum says payers should watch
- Unlicensed dentistry cases, DSO deals, legislation & more: 10 dentistry updates in Virginia
- Missouri system debuts mobile behavioral health unit
- Yale researchers study GLP-1’s potential for SUD
- Texas dental school receives $6.5M to expand pediatric dental, medical programs
- North Carolina autism provider to expand therapy access
- $3M Verdict Links Social Media to Anxiety and Depression
- West Virginia hospital to end OB delivery services
- 6 DSOs making headlines
- California hospital’s finances improve, cash position remains ‘dire’
- 1 in 5 metro markets face inpatient monopoly: 7 notes
- Minnesota system faces uncertainty amid Medicare delays
- Ohio county approves behavioral health crisis center plan
- The White House Delays CDC Pick
- New COVID 'Cicada' Variant Is Spreading — What Experts Want You To Know
- Op-ed: Empathy meets efficiency—how the responsible use of AI can transform Medicare
- Family Caregivers Provide $1 Trillion In Annual Labor, AARP Says
- ‘Health Doesn’t Need to Be Ludacris’: Bayer signs rapper-actor to multivitamin campaign
- Rocket plots measured trajectory for new gene therapy Kresladi after clearance to launch from FDA
- Healthy Lab Results May Mask Future Risks for Kids with Obesity
- At-Home Chemotherapy Is Safe, Feasible, Pilot Study Indicates
- What You Do While Sitting Could Predict Dementia Risk
- New Cholesterol Guidelines: What Patients and Caregivers Need to Know
- Want A Bootlicking Yes Man? Ask An AI Chatbot For Advice, Study Warns
- Specially Coated Implants Better For Breast Cancer Patients, Study Finds
- Trump Team Claims Successes Against ACA Fraud While Pushing for More Controls
- Give and Take: Federal Rural Health Funding Could Trigger Service Cuts
- Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo
- Where are you with EUDAMED?
- Where are you with EUDAMED?
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Why private practice dentistry needs a better model
- CareQuest Innovation Partners, Kno2 collab on medical-dental data integration
- Nonprofit highlights rural opioid care strategies
- Vitana Pediatric & Orthodontic Partners adds Florida practice
- What the Health? From KFF Health News: A Headless CDC
- 20 behavioral health leaders challenge industry assumptions
- Recordati confirms it's weighing CVC Capital buyout offer of $12.6B
- 3 California behavioral health centers to close amid funding shifts
- Indiana bars autism therapy provider from Medicaid billing: Wall Street Journal
- UnitedHealth shareholder sues over proposal to include details on integration in annual proxy
- SCAN taps biopharma, CMS vet Aman Bhandari as its first chief AI officer
- Infosys to acquire Optimum Healthcare IT in $465M deal
- DOJ alleges NewYork-Presbyterian forces payers into anticompetitive 'all-or-nothing' contracts
- FDA Warns Biotech Firm Over Cancer Drug Anktiva Claims
- Bees and Hummingbirds May Be Consuming Small Amounts of Alcohol
- Two States Sue Cord Blood Company Over Misleading Claims
- New WHO Guidance Aims To Speed Tuberculosis Testing
- As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra
- Trump admin delays nomination for new CDC director past deadline
- Outspoken ACIP member steps down amid vaccine panel uncertainty: reports
- Egg-based drugmaker Neion Bio emerges from stealth to cook up multi-product biosimilar collab
- Genentech walks the walk in lupus as sponsor of annual awareness and fundraising event
- Study Reveals How Many Americans Consider Using a Gun
- Massive Study Finds Stress and Grief Don’t Cause Cancer
- Ultra-Processed Foods Harm Fertility In Both Men And Women, Studies Reveal
- Small Daily Habits Can Add Up To Better Heart Health
- Ritalin Might Protect ADHD Kids' Long-Term Mental Health, Study Finds
- Can You Drink Enough Fluids To Prevent Kidney Stones? Maybe Not, New Study Says
- Clasp, loan-linked hiring tool for employers, clinches $20M to expand amid federal loan caps
- Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health
- OpenEvidence rolls out AI medical coding feature
- CDC’s Acting Chief Promises a Return to Stability in a Tumultuous Moment
- Remarks at the Financial Stability Oversight Council Meeting
- RWJF: Between 5M and 10M people could lose Medicaid coverage in 2028 under work requirements
- New therapy animal program aims to support 100K patients, providers
- Pulse check on Lilly's GLP-1 fortunes
- Gen Z nurses prioritize schedule flexibility, need more manager interactions to avoid turnover
- How pharma marketers can capitalize on HCPs’ AI, social media and streaming habits
- Federal Officials Investigate States That Require Abortion Coverage
- Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
- Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion
- FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
- Baby Walkers Sold on Amazon Recalled Over Fall Risk
- Want To Protect Your Brain? Science Says Exercise
- HelloFresh Pizza Recall Issued in 10 States Over Metal Risk
- Clinical Trials Have Too Much Data…That’s the Problem.
- Clinical Trials Have Too Much Data…That’s the Problem.
- CMS reveals new Medicaid model that supports coordination for children with complex needs
- Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices
- Takeda targets $1.3B in cost savings in further restructuring
- Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech
- 'Universal Donor' Blood Supplies Dangerously Low, Study Warns
- Why Stepping Outside May Help You Eat Better
- U.S. Medicine, Science Facing An Online Misinformation Siege, Poll Concludes
- Childhood Obesity Undercuts The American Dream For Some, Study Says
- Inclusive High Schools Benefit All Students, Not Just LGBTQ Teens
- Parental Loss Due to Drugs, Violence Raises Child Death Risk by 2,000%
- As Boehringer touts US launches, board chairman worries EU is 'falling further behind'
- The evolving state of exome and genome sequencing
- Demoralized CDC Workforce Reels From Year of Firings, Funding Cuts, and a Shooting
- An Arm and a Leg: Steep Health Care Costs Steer Americans to Tough Decisions
- Qualified Health locks in $125M in fresh funding to scale enterprise AI at health systems
- Misery Loves [Investment] Company?: Remarks at the 2026 Investment Company Institute Investment Management Conference
- Study: Nearly 1 in 5 pediatric hospital deaths involve sepsis
- As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec
- Opening Remarks at the Digital Asset Summit 2026
- CVS Caremark, FTC reach settlement in insulin pricing case
- UCB unveils plan to build $2B biologics plant near its US headquarters in Atlanta
- PeaceHealth sued over plans to tap out-of-state staffer ApolloMD for Oregon EDs
- New Lyme Disease Vaccine Shows Strong Results in Trial
- TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts
- Highmark reports $175M net loss for 2025 as financial headwinds batter health plan
- Listen to the Latest ‘KFF Health News Minute’
- Abivax hires commercial chief from Takeda to infuse Entyvio expertise into IBD launch prep
- ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode
- Alcohol Prep Pads Recalled Over Bacteria Risk, Cardinal Health Says
- Fewer patients traveled for abortions in 2025 as telehealth care increased, report finds
People across the country are reporting illnesses after microdosing psilocybin with mushroom products from Diamond Shruumz of California. Microdosing involves taking very small doses of psychedelics in specially selected mushroom varieties, typically 10% to 20% of recreational doses.
The Michigan Department of Health and Human Services is warning Michigan's trend setters not to eat Diamond-Shruumz products. The U.S. FDA and Centers for Disease Control and Prevention are investigating illnesses associated with Diamond Shruumz-brand microdosing chocolate bars, infused cones, or microdose and macrodose gummies. The products are labeled as having a blend of mushroom varieties like Reishi and Lion's Mane. Their active ingredient, psilocybin is classified as a hallucinogen. Psilocybin used to cause all kinds of strange behaviors 50 years ago when it was a popular street drug.
Psilocybin mushrooms have been decriminalized in Ann Arbor and Detroit.
MDHHS alerting Michigan residents not to eat Diamond Shruumz-brand chocolate bars, cones and gummies during ongoing FDA investigation
By Lynn Sutfin - June 18, 2024LANSING, Mich.-The Michigan Department of Health and Human Services (MDHHS) and the Food and Drug Administration (FDA) are urging Michigan residents not to eat, sell or serve any flavor of Diamond Shruumz-brand Microdosing Chocolate Bars, Infused Cones or Micro Dose and Macro Dose gummies, and instead throw them away. The products are labeled as containing a proprietary blend of mushrooms such as reishi and lion’s mane.
“People in multiple states have become ill after eating these products, reporting a variety of severe symptoms,” said Dr. Natasha Bagdasarian, chief medical executive. “As these products look similar to candy, we urge parents and caregivers to consider discussing this information with their teens even though they are intended for individuals 18 and older. We are advising that everyone avoid these products.”
As of Friday, June 7, the FDA and Centers for Disease Control and Prevention (CDC), in collaboration with America’s Poison Centers and state and local partners, are investigating a series of illnesses associated with eating Diamond Shruumz-brand products. The FDA is working to determine the cause of these illnesses.
A total of 26 illnesses have been reported from 16 states, including Alabama, Arizona, California, Indiana, Kentucky, Maryland, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, North Carolina, Pennsylvania, South Carolina and Tennessee. To date, there are no reported cases in Michigan.
Of those who became ill, 25 people reported seeking medical care, with 16 being hospitalized. No deaths have been reported. People who became ill from eating Diamond Shruumz-brand products reported a variety of severe symptoms including seizures, central nervous system depression (loss of consciousness, confusion, sleepiness), agitation, abnormal heart rates, hyper/hypotension, nausea and vomiting.
Diamond Shruumz-brand products can be purchased online or at a variety of retail locations nationwide, including smoke/vape shops or places that sell hemp-derived or CBD products.
Retailers should not sell or distribute any of these products. Instead, hold these products until further direction is given by the FDA.
Those who become ill after consuming these products should seek medical treatment. They can also call the Poison Help Line at 800-222-1222 to report symptoms and seek information. Callers should let Poison Control know they have recently consumed a Diamond Shruumz-brand chocolate bars, cone or gummies.
Health care providers should report these illnesses to their local health department or the Poison Help Line at 800-222-1222.
MDHHS will continue to monitor incoming information from FDA. Consumers and health care providers can monitor updates about this investigation at Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies (June 2024) | FDA.
Physicians or residents with questions or concerns can contact MDHHS by calling 844-464-7327 or emailing mdhhs-eht@michigan.gov.
FDA is now investigating one death associated with these Diamond Shruumz microdose products, and it is now believed that the toxic agent which caused these sicknesses is muscimol not psilocybin:
https://www.upi.com/Health_News/2024/07/03/Diamond-Shruumz-death/5371719992921/
FDA probing death potentially linked to recalled microdosing candies
By Darryl Coote - July 3, 2024July 3 (UPI) -- Federal food safety officials are investigating a potential death linked to ingesting recalled microdosing chocolates and candies that have sickened dozens of people across the United States.
All Diamond Shruumz-brand chocolates and gummies were recalled late last month over the products containing toxic levels of muscimol, a chemical found in some mushrooms that can cause seizures, involuntary muscle contractions and a loss of consciousness, among other issues.
At least 48 illnesses linked to the edibles have been reported in 24 states as of Monday, the Food and Drug Administration said in an update to the recall on Tuesday.
Twenty-seven of the patients have been hospitalized, it said, adding that there is one potentially associated death under investigation.
American Poison Centers in a statement added that it has received 82 reports of exposure associated with the Diamond Shruumz products, including 48 cases of severe illness, of which all but two sought medical attention.
The FDA said those who became ill after eating Diamond Shruumz-brand products reported a variety of severe symptoms, including seizures, central nervous system depression, agitation, abnormal heart rates, nausea and vomiting.
Diamond Shruumz is instructing its customers to not eat their products amid the investigation. It said in a statment on its website that those who became ill from eating their products had consumed "the entire chocolate bar and some products containing higher levels of muscimol than normal."
The FDA is also recommending not to eat, sell or serve any flavor of Diamond Shruumz-brand chocolate bars, cones or gummies. Those in possession of the recalled products are being instructed to either discard them or return them to the company for a refund.
The products affected by the recall were sold online as well as at retail stores that sell such products, including smoke and vape shops.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.

















